TG Therapeutics(NASDAQ) TGTX

TG Therapeutics, Inc. helps people manage multiple sclerosis. They make medicines for cancers and autoimmune disorders. These treatments help patients face long-term health challenges.

Targeted Treatments for Patients

• BRIUMVI (intravenous): A one-hour infusion given twice a year to treat adults with relapsing forms of multiple sclerosis.
• Subcutaneous Ublituximab: An investigational version of the main drug delivered by an injection under the skin.
• Azer-cel: An off-the-shelf cell therapy designed to treat progressive forms of multiple sclerosis and other autoimmune diseases.

Milestones in Growth

• Launched BRIUMVI in the United States in Jan. 2023 for adults with relapsing forms of multiple sclerosis.
• Partnered with Neuraxpharm in Aug. 2023 for the commercialization of BRIUMVI outside of North America.
• Began a Phase 2 trial in July 2026 to evaluate treatment for adults with treatment-resistant schizophrenia.
• Dosed the first patient with progressive multiple sclerosis in a Phase 1 trial for azer-cel in Aug. 2025.
• Announced positive topline data from the Phase 3 ENHANCE trial for simplified dosing in May 2026.

What Makes the Firm Unique

TG Therapeutics uses specialized antibody engineering to create treatments that may work more effectively for immune system disorders. Its focus on reducing infusion times to one hour provides a convenience advantage for patients and healthcare providers.

A Look at the Books

• Net product revenue reached $235.8 million for the three-month period ended June 30, 2026, up from $138.8 million year over year.
• The company reported net income of $7.8 million for the three-month period ended June 30, 2026.
• Total revenue for the six-month period ended June 30, 2026, was $445.3 million.
• The firm held $612.3 million in cash, cash equivalents, and investment securities as of June 30, 2026.
• Market capitalization was $7.6 billion based on recent market data.

Bottom Line

TG Therapeutics has successfully evolved from a clinical research organization into a profitable commercial biopharmaceutical business. Its expansion into international markets and new drug delivery methods demonstrates its ability to adapt and grow.